ClinicalTrials.gg

Program

BET Inhibitor TQB3617

Also written as “TQB3617 Capsules” and “TQB3617”.

In Sino Biopharmaceutical’s pipeline, BET抑制剂. Its studies are mostly in Primary Myelofibrosis, led by Sino Biopharmaceutical.

Furthest: phase 2, since Nov 2, 20232 company-led studies, 1 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical21 open or runningphase 2since Nov 2, 2023Nov 4, 2021Dec 2026phase 2 · NCT06122831
  • Named in Sino Biopharmaceutical’s own pipeline as TQB3617, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 4, 2021First study: phase 1 study in Advanced Malignant TumorsFirst studyNCT05110807 · 38 enrolled · China
  2. Nov 2, 2023Phase 2 study in Primary MyelofibrosisNCT06122831 · 92 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in Primary MyelofibrosisNCT06122831

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06122831Primary Myelofibrosis · China2RecruitingDec 202692
NCT05110807Advanced Malignant Tumors · China1UNKNOWNOct 202238

How it is read

Names in the registry

  • “TQB3617 Capsules”, 1 entry
  • “TQB3617”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.